These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29372508)

  • 1. Early candidate biomarkers found from urine of glioblastoma multiforme rat before changes in MRI.
    Ni Y; Zhang F; An M; Yin W; Gao Y
    Sci China Life Sci; 2018 Aug; 61(8):982-987. PubMed ID: 29372508
    [No Abstract]   [Full Text] [Related]  

  • 2. Dichloroacetate induced intracellular acidification in glioblastoma: in vivo detection using AACID-CEST MRI at 9.4 Tesla.
    Albatany M; Li A; Meakin S; Bartha R
    J Neurooncol; 2018 Jan; 136(2):255-262. PubMed ID: 29143921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary D-asparagine level is decreased by the presence of glioblastoma.
    Nakade Y; Kinoshita M; Nakada M; Sabit H; Ichinose T; Mita M; Yuno T; Noguchi-Shinohara M; Ono K; Iwata Y; Wada T
    Acta Neuropathol Commun; 2024 Aug; 12(1):122. PubMed ID: 39164793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implanting Glioblastoma Spheroids into Rat Brains and Monitoring Tumor Growth by MRI Volumetry.
    Löhr M; Linsenmann T; Jawork A; Kessler AF; Timmermann N; Homola GA; Ernestus RI; Hagemann C
    Methods Mol Biol; 2017; 1622():149-159. PubMed ID: 28674808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastoma multiforme versus pleomorphic xanthoastrocytoma with anaplastic features in the pathological diagnosis: a case report.
    Yamada SM; Murakami H; Tomita Y; Nakane M; Shibui S; Takahashi M; Kawamoto M
    Diagn Pathol; 2016 Jul; 11(1):65. PubMed ID: 27449352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
    Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
    Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease.
    Mallawaaratchy DM; Hallal S; Russell B; Ly L; Ebrahimkhani S; Wei H; Christopherson RI; Buckland ME; Kaufman KL
    J Neurooncol; 2017 Jan; 131(2):233-244. PubMed ID: 27770278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour.
    Smith SJ; Diksin M; Chhaya S; Sairam S; Estevez-Cebrero MA; Rahman R
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
    Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma.
    Corroyer-Dulmont A; Pérès EA; Gérault AN; Savina A; Bouquet F; Divoux D; Toutain J; Ibazizène M; MacKenzie ET; Barré L; Bernaudin M; Petit E; Valable S
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):682-94. PubMed ID: 26537287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities.
    Stevenson CB; Ehtesham M; McMillan KM; Valadez JG; Edgeworth ML; Price RR; Abel TW; Mapara KY; Thompson RC
    Neurosurgery; 2008 Sep; 63(3):560-9; discussion 569-70. PubMed ID: 18812968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (99m)Tc-ixolaris targets glioblastoma-associated tissue factor: in vitro and pre-clinical applications.
    Barboza T; Gomes T; Mizurini DM; Monteiro RQ; König S; Francischetti IM; Signoretti PV; Ramos IP; Gutfilen B; Souza SA
    Thromb Res; 2015 Aug; 136(2):432-9. PubMed ID: 26070446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative proteomics reveals the novel co-expression signatures in early brain development for prognosis of glioblastoma multiforme.
    Yu X; Feng L; Liu D; Zhang L; Wu B; Jiang W; Han Z; Cheng S
    Oncotarget; 2016 Mar; 7(12):14161-71. PubMed ID: 26895104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients.
    Cordova JS; Shu HK; Liang Z; Gurbani SS; Cooper LA; Holder CA; Olson JJ; Kairdolf B; Schreibmann E; Neill SG; Hadjipanayis CG; Shim H
    Neuro Oncol; 2016 Aug; 18(8):1180-9. PubMed ID: 26984746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Radiomics and Metabolic Tumor Volumes in Radiation Treatment of Glioblastoma Multiforme.
    Lopez CJ; Nagornaya N; Parra NA; Kwon D; Ishkanian F; Markoe AM; Maudsley A; Stoyanova R
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):586-595. PubMed ID: 28011044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced magnetic resonance imaging to support clinical drug development for malignant glioma.
    Kassubek R; Müller HP; Thiele A; Kassubek J; Niessen HG
    Drug Discov Today; 2021 Feb; 26(2):429-441. PubMed ID: 33249294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Search for a diagnostic/prognostic biomarker for the brain cancer glioblastoma multiforme by 2D-DIGE-MS technique.
    Banerjee HN; Mahaffey K; Riddick E; Banerjee A; Bhowmik N; Patra M
    Mol Cell Biochem; 2012 Aug; 367(1-2):59-63. PubMed ID: 22547198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of DCE-MRI parameters for brain tumors through implementation of physiologically-based pharmacokinetic model approaches for Gd-DOTA.
    Spanakis M; Kontopodis E; Van Cauter S; Sakkalis V; Marias K
    J Pharmacokinet Pharmacodyn; 2016 Oct; 43(5):529-47. PubMed ID: 27647272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upfront boost Gamma Knife "leading-edge" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy.
    Duma CM; Kim BS; Chen PV; Plunkett ME; Mackintosh R; Mathews MS; Casserly RM; Mendez GA; Furman DJ; Smith G; Oh N; Caraway CA; Sanathara AR; Dillman RO; Riley AS; Weiland D; Stemler L; Cannell R; Abrams DA; Smith A; Owen CM; Eisenberg B; Brant-Zawadzki M
    J Neurosurg; 2016 Dec; 125(Suppl 1):40-49. PubMed ID: 27903197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic urinary proteomic analysis in a Walker 256 intracerebral tumor model.
    Zhang L; Li Y; Meng W; Ni Y; Gao Y
    Cancer Med; 2019 Jul; 8(7):3553-3565. PubMed ID: 31090175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.